If life sciences companies address these aspects early, they can successfully plan commercial launches and enable future adaptability.
In brief
- To manage compliance and reduce costs, companies should consider customs and VAT complexities.
- Driven by the COVID-19 pandemic, life sciences companies have focused on increasing supply chain flexibility to reduce future disruption.
- Opportunities exist to yield savings in customs and VAT compliance, specifically when identified early in the supply chain design.
Source EY
